<DOC>
	<DOCNO>NCT02603055</DOCNO>
	<brief_summary>Hepatitis E characteristic sporadic local epidemic around world , mainly infect adult age 15 40 year old , result infection rate range 1 % 15 % . The investigational hepatitis E vaccine recombinant aluminium-adjuvant hepatitis E vaccine . This single center , randomize , blind , parallel-controlled phase Ib clinical trial . This study determine safety immunogenicity investigational recombinant hepatitis E vaccine healthy adult 16 65 year .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Recombinant Hepatitis E Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 16 65 year normal intelligence . Negative antibody hepatitis E test . No plan go long time within 9 month . Able understand content inform consent willing sign inform consent General good health establish medical history physical examination . Able willing complete seclude study process whole study followup period . No history hepatitis B , hepatitis C hepatitis E ( Patients diagnose hepatitis B , hepatitis C hepatitis E town ) Axillary temperature ≤37.0°C day enrollment Woman pregnant , breastfeed planning pregnant study period Allergic history vaccination drug , allergic ingredient Hepatitis E vaccine History serious adverse reaction vaccination , allergy , urticaria , breathe difficulty , angioneurotic oedema abdominal pain Autoimmune disease immunodeficiency Asthma unstable need emergency treatment , hospitalization , oral intravenous corticosteroid within two year Type I II diabetes , include gestational diabetes History thyroidectomy , need treatment thyroid disease past 12 month History serious angioneurotic edema past 3 year , need treatment past 2 year Severe hypertension , blood pressure still 150/100 mmHg drug maintenance treatment Abnormal coagulation function ( coagulation factor deficiency , coagulation disorder , platelet abnormality ) coagulation disorder diagnose doctor . Patients active definite cure malignant tumor , may recur study period . Epilepsy , include alcohol epilepsy first 3 year abstinence simple epilepsy without need treatment past 3 year Asplenia functional asplenia , asplenia splenectomy circumstance Guillain Barre Syndrome Prior administration immunodepressant , cytotoxic corticosteroid ( include corticosteroid therapy allergic rhinitis acute non concurrent dermatitis ) treatment last 6 month Prior administration immune globulin last 3 month Prior administration research medicine last 1 month Prior administration attenuate vaccine last 1 month Prior administration subunit inactivate vaccine last 14 day , pneumococcal Vaccine Current antituberculosis prophylaxis therapy Fever ( axillary temperature 38.0℃ ) 3 day vaccination acute disease , systemic application antibiotic antiviral therapy past five day Unable comply study requirement due psychological situation , past present history mental disease , twostage affective psychosis well control past two year ; mental disease need medical treatment , suicidal tendency past five year Any condition opinion investigator may interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>Hepatitis E</keyword>
</DOC>